Reports on Xenografts Findings from Uppsala University Provide New Insights (Radionuclide Therapy of HER2-Expressing Xenografts Using [<superscript>177</superscript>Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab).
In: Immunotherapy Weekly, 2023-05-30, S. 1577-1577
serialPeriodical
Zugriff:
Keywords: Antineoplastic Monoclonal Antibodies; Antineoplastics; Biotechnology; Drugs and Therapies; HER2 Inhibitors; Health and Medicine; Immunologic Agents; Medical Devices; Monoclonal Antibodies; Pharmaceuticals; Trastuzumab Therapy; Tyrosine Kinase Inhibitors; Xenografts; Xenotransplantion EN Antineoplastic Monoclonal Antibodies Antineoplastics Biotechnology Drugs and Therapies HER2 Inhibitors Health and Medicine Immunologic Agents Medical Devices Monoclonal Antibodies Pharmaceuticals Trastuzumab Therapy Tyrosine Kinase Inhibitors Xenografts Xenotransplantion 1577 1577 1 05/29/23 20230530 NES 230530 2023 JUN 2 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- New research on xenografts is the subject of a new report. According to the news editors, the research concluded: "A combination of therapies utilizing [ SP 177 sp Lu]Lu-ABY-027 and trastuzumab improved the treatment outcome in comparison with monotherapies using these agents. [Extracted from the article]
Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Reports on Xenografts Findings from Uppsala University Provide New Insights (Radionuclide Therapy of HER2-Expressing Xenografts Using [<superscript>177</superscript>Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab).
|
---|---|
Zeitschrift: | Immunotherapy Weekly, 2023-05-30, S. 1577-1577 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1090-8625 (print) |
Sonstiges: |
|